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Abstract
The randomized controlled trial is commonly used by both epidemiologists and economists to test
the effectiveness of public health interventions. Yet we have noticed differences in practice
between the two disciplines. In this article, we propose that there are some underlying differences
between the disciplines in the way trials are used, how they are conducted and how results from
trials are reported and disseminated. We hypothesize that evidence-based public health could be
strengthened by understanding these differences, harvesting best-practice across the disciplines
and breaking down communication barriers between economists and epidemiologists who
conduct trials of public health interventions.
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Introduction
The randomized controlled trial is widely used in biomedical and so-
cial science. Trials of public health interventions—as opposed to
clinical trials (Collier 2009)—date back at least to the study of tu-
berculosis prophylaxis in the 1960s (Comstock et al. 1967).
Prominent examples in economics of the early use of trials include
the RAND health insurance experiment (Manning et al. 1987). But
it is in the past two decades that there has been a surge of interest in
trials among economists, especially those working in international
development. This has led to debate about their usefulness (Deaton
2010). Such debates are also alive and well in public health (Bonell
et al. 2012).
Epidemiologists and economists both use trials to test the impact
of public health interventions. For example, both epidemiologists
and economists have tested the impact of deworming on education
outcomes (Awasthi et al. 2013; Miguel and Kremer 2004), and the
effects of cash-transfers on HIV (Baird et al. 2012; Pettifor et al.
2016). However, we have noticed differences in practice between
the two disciplines. By understanding better these differences and
looking at best practices across the two disciplines, we hypothesize
that evidence-based public health can be strengthened.
In this article, we propose that while there is both significant
overlap between, and heterogeneity of practice within, the two dis-
ciplines, there are three underlying areas of difference in the way
economists and epidemiologists undertake trials: the purpose for
which trials are used, the conduct of trials and the way that the
results of trials are reported and disseminated. We describe these
differences, illustrating with examples and end by suggesting some
areas where best practice could be transported in either direction
across the disciplinary divide, and call for ongoing efforts to support
inter-disciplinary communication and collaboration. The focus of
the paper is on public health interventions that typically have a be-
havioural element to them; we are less interested in clinical drugs tri-
als where the intervention works primarily through a biological
mechanism and can be tested using double-blind placebo-controlled
trials. In an article of this nature, we recognize that it is difficult to
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avoid making generalizations. Heterogeneity within the disciplines
probably dwarfs that between them. Moreover, we have not system-
atically reviewed the literature and think it likely that counter-
examples to those we have raised in the paper can be identified.
Nevertheless, we believe that our observations will resonate with
readers and stimulate debate.
How are trials used?
Trials offer a transparent approach to get an unbiased estimate of
the causal effect of an intervention on an outcome, in a particular
setting. They address the question: does it work? Both epidemiolo-
gists and economists use trials to evaluate whether an intervention
works. Trials of this nature are sometimes referred to as ‘effective-
ness trials’ (in epidemiology) or ‘policy evaluations’ (in economics).
The intervention is delivered in conditions that are (argued to be)
similar to real-world implementation of the intervention.
Public health interventions often aim to change human behaviour,
be that of healthcare providers, patients or the public in general.
However, since most public health interventions are social, the effects
are likely to vary when tried with different populations in different
places, and even at different times. We need to understand why an
intervention worked, and for whom, if the findings are to be useful in
other settings.
Both disciplines support the idea of replicating trials in different set-
tings with a view to making findings more generalizable (Angrist and
Pischke 2010; Cook and Campbell 1979). However, our observation is
that beyond replication, economists and epidemiologists confront the
challenge of addressing external validity in different ways, and this af-
fects the reasons why, and how, they do trials in the first place. There
is also the fact that economics is a social science—with a rich tradition
of developing formal theory of behaviour in the mathematical expres-
sion of a set of ideas and principles—in a way that epidemiology is not.
Epidemiologists tend to design trials in multi-disciplinary teams, in
part because there is no generally accepted model of human behaviour
within epidemiology. They bring in experts to help develop interven-
tions and, in doing so, draw on theory from a range of other disciplines,
such as health promotion. Some evaluations are informed by a so-
called theory of change (Breuer et al. 2016) that provides a conceptual
map of how the intervention is intended to work, grounded in the con-
text where the trial is taking place. To understand how an intervention
worked, mechanisms of effect are explored through process evaluation
and the use of qualitative research methods (Moore et al. 2015).
Economists appear to favour other strategies to help generalize
findings. We observe that economists seem more willing to have mul-
tiple trial arms to test variations in the intervention along dimensions
that can tell us something about how it works while epidemiologists
tend to focus on simple trials to test the best designed and most policy
relevant candidate intervention. For example, in an epidemiologist-
led trial of conditional cash transfers for HIV prevention in rural
South Africa, there were just two study arms: families in the interven-
tion arm received $36 per month conditional on school attendance;
families in the control arm received nothing (Pettifor et al. 2016). In
contrast, in an economist-led trial of cash for HIV prevention in
Malawi, almost no two individuals in the intervention arm received
exactly the same amount of money, since amounts of cash that went
to different recipients were varied randomly, as was the conditional-
ity attached (Baird et al. 2012).
Some economists argue for greater use of ‘mechanism experi-
ments’, where the intervention is not designed to be implementable
in the real-world, but instead helps to test a behavioural theory
(Ludwig et al. 2011). For example, a two-stage pricing design was
used in a trial in Zambia to test several competing theories of why
higher prices of health products increase actual use (Ashraf et al.
2010). Epidemiologists, it should be stressed, do use trials to test dir-
ectly theories relevant to public health, but often these relate to a
biological mechanism rather than behavioural theory. For example,
the recent HPTN052 trial tested the theory that successful antiretro-
viral treatment of an HIV-infected individual would reduce their in-
fectiousness, and that this in turn could reduce transmission to
partners (Cohen et al. 2016). HIV-discordant couples were enrolled
to the placebo-controlled study but the specific intervention with
couples was intended as a ‘proof of principle’ to inform later trials
of scalable approaches to preventing HIV transmission through the
provision of ARVs to those infected with HIV. But on balance we
suggest that economists appear more willing than epidemiologists to
explicitly design trials that test aspects of human behaviour.
As a follow on, economists sometimes use ‘structural models’ to
incorporate or interpret the findings from a trial (Attanasio et al.
2012; Heckman 2010; Todd and Wolpin 2006). In essence, this
approach develops a model of behaviour making explicit its assump-
tions, takes the experimental results, fits the model and makes
predictions about the effect of changing the policy or the setting
(Card et al. 2011; Ludwig et al. 2011). This approach to making
predictions draws on the rich tradition in economics of developing
formal theory and combining it with empirical research. There is a
parallel in epidemiology where empirical findings are extrapolated
from one setting to another using mathematical models of infectious
disease transmission (White et al. 2008) that sometimes also incorp-
orate aspects of human behaviour (Medley et al. 2015).
How are trials conducted?
How a trial is undertaken and how the data are analysed affect the
risk of drawing the wrong conclusions about the effects of the inter-
vention. Both disciplines take this risk seriously, but we note that
Key Messages
• The randomized controlled trial is commonly used by both epidemiologists and economists to test the effectiveness of
public health interventions.
• There is convergence between disciplines in a number of areas, most notably in the appreciation for protocols,
pre-specifying outcomes and the analysis approaches and registering trials.
• Differences between disciplines suggests that more can be done to incorporate behavioural theory into trials, improve
the reporting of trial results and share data.
• We hypothesize that evidence-based public health can be strengthened by understanding differences in how economists
and epidemiologists conduct trials of public health interventions and harvesting best-practice across the disciplines.
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there appear to be differences in what are considered standard, or
best, practices in each discipline.
It has long been standard in epidemiology to publish study proto-
cols and register trials. Protocols describe the entire trial in detail: the
hypothesis, rationale, study population, study design, primary and
secondary outcomes, sample size calculations, data collection and
analysis methods, and timeline for the study. Detailed statistical ana-
lysis plans are usually specified before a trial is complete and made
available in the public domain. Trial registration—to limit publication
bias—is now a requirement for most journals, and there are many
registers, such as the ISRCTN Registry, Clinicaltrials.gov, the registry
of the National Institutes of Health in the United States and the EU
Clinical Trials registry. It should be noted that these practices have
been strongly influenced by the developing practice of trials in medi-
cine. While these procedural aspects of trials have historically been
neglected by economists, recent years have seen convergence with the
practice of epidemiologists (AEA 2016; Casey et al. 2012).
In epidemiology trials, for example, the study size is usually deter-
mined based on having sufficient power for a hypothesized effect on a
single primary outcome (Smith et al. 2015). In contrast, power calcu-
lations have not traditionally been used by economists. However, as
experimental approaches have gained in popularity, the statistical de-
sign of experiments has now become part of econometric textbooks.
The use of power calculations to set the sample size is now common,
even if these details are rarely reported in journal articles (Cameron
and Trivedi 2005; Duflo et al. 2008). The evidence, beyond just trials,
suggests that most empirical research in both economics and health is
underpowered (Ioannidis et al. 2017; Turner et al. 2013).
Economists tend to analyse trials using ordinary least squares re-
gression, regardless of whether the outcome is continuous (e.g. in-
come) or dichotomous (e.g. being vaccinated). In epidemiology,
trials are often analysed using simple statistics or regression methods
designed for the specific type of outcome under study. Common
analysis methods include logistic regression for binary outcomes,
Poisson or Cox models for time-to-event data, or linear regression
for continuous outcome data. In both disciplines, these modelling
approaches make it straightforward to include the baseline charac-
teristics of the units to improve precision and examine effects within
different sub-groups of the population. Confidence intervals are
near-universally reported by epidemiologists, while in economics the
reporting of standard errors is the norm. It is worth noting that
standard errors are not useful for ratio effect estimators—often used
in epidemiology trials—because of highly skewed distributions.
Epidemiologists pre-specify a hierarchy of outcomes: a primary
outcome and a number of secondary outcomes. Considerable emphasis
and effort is given to objectively-measured clinical outcomes.
Outcomes that were not pre-specified are analysed, but the results of
such analyses are, at least in theory, treated with caution because of
the potential for false positive findings to arise as a result of selective
reporting. Economists appear to place less emphasis on such a hier-
archy, in some cases specifying a large number of outcomes and then
using statistical methods to deal with the problem of multiple hypoth-
esis testing (Anderson 2008; Kling et al. 2007). This is attractive when
interventions are multi-faceted, such as, for example, poverty reduction
or agricultural projects that produce effects on many outcomes,
none of which can be considered more important a priori. There is
also recognition that such interventions can have unexpected and
unintended effects which are important to capture.
Finally, economists appear more willing to give higher profile to
analyses that go beyond the basic analysis of a trial. This might in-
clude, for example, using random assignment as an instrumental
variable to estimate effects of treatment on the treated as opposed
to intent-to-treat estimates, when there is partial compliance
(Finkelstein et al. 2012). Other methods, such as quantile regression
analysis and regression discontinuity designs, have been used in the
analysis of trials to understand variation in who benefits from an
intervention (Banerjee et al. 2015; Duflo et al. 2011). While such
techniques are also used by statistical epidemiologists, the primary
analysis of epidemiology trials of public health interventions appears
to strongly privilege transparent, simple, pre-specified analysis of a
limited number of outcomes.
How are trial findings reported and
disseminated?
Researchers in both fields want trials to inform policy and improve
lives. However, the approaches of the two disciplines to reporting
and dissemination appear different, perhaps reflecting the research-
into-policy routes that have historically been common in each
discipline.
Epidemiological public health gives primacy to evidence synthe-
sis, through systematic reviews and meta-analysis, as established in
clinical medicine. The World Health Organization plays a normative
role in advising on best practice, and has an established approach
to evidence appraisal based on systematic review. Systematic
reviews combine all relevant evidence and quantify the quality of
the evidence using methods intended to reduce the risk of bias or the
role of reviewer subjectivity. In contrast, economics does not appear
to have such a tradition or well-established architecture for doing
systematic reviews. With one notable exception (Croke et al. 2016),
reviews conducted by economists tend to be narrative in nature, in-
clude an appraisal of relevant theory, and are conducted by a leader
in a field rather than according to an agreed method. The
generalizability of the findings of a study is thus more likely to be
argued within trial papers themselves.
To facilitate the research-into-reviews route, trialists in medicine
and public health have developed the Consolidated Standards of
Reporting Trials (CONSORT) statement that standardizes report-
ing, with a strong focus on showing the completeness of data and
loss to follow up (Begg et al. 1996). While the guidelines are for re-
porting, they also shape the way that epidemiologists conduct trials
by pre-specifying the information to be collected. A consequence of
the strict template is an expectation for quick publication after data
collection, since analysis decisions should have been made at the
protocol stage. Economists are not formally guided by such stand-
ards which has meant that, historically at least, papers published in
economics journals, while considerably longer, have not always pro-
vided sufficient information for the assessment of risk of bias
(Boone et al. 2013). Economists do have a strong tradition of, and
expectation towards, the sharing of data and analysis code that may
in part compensate for the lack of stringent guidelines for reporting.
It seems likely that epidemiologists will follow suit in this respect as
medical journals increasingly require data to be made publicly avail-
able (Warren 2016), but at the current time the practices appear
quite different.
A final difference we note is in the use of working papers. These
are draft versions of papers that economists circulate online and at
seminars to gather criticism, establish ‘property rights’ over an idea,
and garner interest. The time between data collection and formal publi-
cation appears much longer in economics (Card and DellaVigna 2013)
than in epidemiology. The practice of presenting working papers at
conferences and seminars before publication allows for a thorough
public review, in addition to the peer-review process required by
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journals. However, since working papers can be revised, misleading
conclusions may be promulgated while the delay in producing a final
version poses a challenge for contributing to policy in a timely manner.
Way forward
The design of public health trials often brings perspectives from
clinical medicine and the behavioural and social sciences. Key deci-
sions about the purpose, design, conduct and reporting of trials
often lie with either epidemiologists or, increasingly, economists.
These scientists share a common appreciation of the benefits of
trials. We think it likely that there is considerable heterogeneity in
practices within each discipline. However, we propose that there are
key areas in which the two disciplines differ and we have sought to
pin point where these differences might lie. We acknowledge that
counter-examples to the generalizations we have raised throughout
this paper can be made and future research should systematically re-
view the literature for more robust evidence of such differences and
their implications. Nevertheless, we have time and again heard from
our colleagues of instances where communication and understand-
ing across the disciplines, even among those using similar research
designs to address similar questions, is challenging. We wish to see
greater collaboration across disciplines, and perceive that there have
been instances of confusion and miscommunication that work
against this. It is these that we seek to break down, and our paper is
an attempt to identify factors at the root of this misunderstanding so
that best practices from each discipline can be taken up.
Recent growth of the use of trials in economics is mostly a posi-
tive development. The fact that trials lower the risk of bias com-
pared to alternative designs is why epidemiologists and economists
have embraced them. We see convergence in the appreciation for
protocols, pre-specifying outcomes and the analysis approaches that
will be used, and registering protocols with a third party to reduce
publication bias. Increased data-sharing is another element of the
transparency agenda now supported by both disciplines. This
convergence has come from best practices already being shared
across disciplines.
Trials led by economists often seek to incorporate behavioural
theory into the design of trials or in the interpretation of results. For
example, trials of financial incentives that use multiple treatments to
map the shape of the relationship between the size of an incentive
and the outcome is motivated by theory that helps to generalize
findings (Cohen and Dupas 2010). While such ‘dosing’ approaches
are common in trials of medicines, we perceive they are less common
in trials of public health interventions designed by epidemiologists.
There is an increasing emphasis on theories of change and process
evaluations alongside such trials to assess implementation, mechan-
isms of change and relevant contextual factors. However, there may
be something for epidemiologists to learn from economists in how
they use relevant theory to both inform evaluations of behavioural
interventions and interpret their results.
Economics has a strong tradition based around working papers.
Unlike in epidemiology and the medical sciences, papers can take sev-
eral years to be published in the most reputable journals (Card and
DellaVigna 2013). While there is much credit in the debate and
discussion this system catalyses, we see a tension between this way of
working and the desire for results from trials to rapidly make it into
evidence synthesis processes and thereby inform policy. We suggest
that the primary pre-specified analyses of all trials conducted by
economists and epidemiologists alike should be reported in short,
CONSORT-format products as soon as is feasible. This should not
get in the way of the longer process of challenge and theoretical
development that is current practice in economics.
Finally, we believe it important that synthesis for policy makers
should use the whole evidence base in an unbiased way. This implies
a need for understanding of different types of evidence within review
teams, and a greater appreciation of similarities and differences
between disciplines. It also implies we need to make work more
visible across our disciplinary and publishing divide to support
better evidence-based policy making in public health.
Funding
Richard Hayes receives support from the MRC UK and DFID - MRC Grant
Reference MR/K012126/1. This award is jointly funded by the UK Medical
Research Council (MRC) and the UK Department for International
Development (DFID) under the MRC/DFID Concordat agreement and is also
part of the EDCTP2 programme supported by the European Union.
Conflict of interest statement. None declared.
References
AEA. 2016. American Economic Association’s registry of randomized
controlled trials. Available at https://www.socialscienceregistry.org/.
Anderson ML. 2008. Multiple inference and gender differences in the effects
of early intervention: a reevaluation of the abecedarian, perry preschool,
and early training projects. Journal of the American Statistical Association
103: 1481–95.
Angrist JD, Pischke J-S. 2010. The credibility revolution in empirical eco-
nomics: how better research design is taking the con out of econometrics.
Journal of Economic Perspectives 24: 3–30.
Ashraf N, Berry J, Shapiro JM. 2010. Can higher prices stimulate product use?
Evidence from a field experiment in Zambia. American Economic Review
100: 2383–413.
Attanasio OP, Meghir C, Santiago A. 2012. Education choices in Mexico:
using a structural model and a randomized experiment to evaluate
PROGRESA. Review of Economic Studies 79: 37–66.
Awasthi S, Peto R, Read S et al. 2013. Population deworming every 6 months
with albendazole in 1 million pre-school children in North India: DEVTA, a
cluster-randomised trial. Lancet 381: 1478–86.
Baird SJ, Garfein RS, McIntosh CT, Ozler B. 2012. Effect of a cash transfer
programme for schooling on prevalence of HIV and herpes simplex type 2 in
Malawi: a cluster randomised trial. Lancet 379: 1320–9.
Banerjee A, Duflo E, Goldberg N et al. 2015. Development economics. A
multifaceted program causes lasting progress for the very poor: evidence
from six countries. Science 348: 1260799.
Begg C, Cho M, Eastwood S et al. 1996. Improving the quality of reporting of
randomized controlled trials. The CONSORT statement. JAMA 276: 637–9.
Bonell C, Fletcher A, Morton M, Lorenc T, Moore L. 2012. Realist rando-
mised controlled trials: a new approach to evaluating complex public health
interventions. Social Science &Medicine 75: 2299–306.
Boone P, Eble A, Elbourne D. 2013. Risk and Evidence of Bias in Randomized
Controlled Trials in Economics. Centre for Economic Performance, LSE,
CEP Discussion Papers.
Breuer E, Lee L, De Silva M, Lund C. 2016. Using theory of change to design
and evaluate public health interventions: a systematic review. Implementation
Science 11: 63.
Cameron AC, Trivedi PK. 2005. Microeconometrics: Methods and
Applications. Cambridge: Cambridge University Press.
Card D, DellaVigna S. 2013. Nine facts about top journals in economics.
Journal of Economic Literature 51: 144–61.
Card D, DellaVigna S, Malmendier U. 2011. The role of theory in field experi-
ments. Journal of Economic Perspectives 25: 39–62.
Casey K, Glennerster R, Miguel E. 2012. Reshaping institutions: evidence on
aid impacts using a Preanalysis Plan. Quarterly Journal of Economics 127:
1755–812.
4 Health Policy and Planning, 2018, Vol. 0, No. 0
Downloaded from https://academic.oup.com/heapol/advance-article-abstract/doi/10.1093/heapol/czy028/4955260
by London School of Hygiene & Tropical Medicine user
on 02 May 2018
Cohen J, Dupas P. 2010. Free distribution or cost-sharing? Evidence from a
randomized malaria prevention experiment. Quarterly Journal of
Economics 125: 1–45.
Cohen MS, Chen YQ, McCauley M et al. 2016. Antiretroviral therapy for the
prevention of HIV-1 transmission. The New England Journal of Medicine
375: 830–9.
Collier R. 2009. Legumes, lemons and streptomycin: a short history of the
clinical trial. CMAJ 180: 23–4.
Comstock GW, Ferebee SH, Hammes LM. 1967. A controlled trial of
community-wide isoniazid prophylaxis in Alaska. The American Review of
Respiratory Disease 95: 935–43.
Cook T, Campbell D. 1979. Quasi-Experimentation: Design and Analysis
Issues for Field Settings. Boston: Houghton Mifflin.
Croke K, Hamory Hick J, Hsu E, Kremer M, Miguel E. 2016. Does mass
deworming affect child nutrition? Meta-analysis, cost-effectiveness and stat-
istical power. Policy Research Working Paper 7921. Washington DC:
World Bank.
Deaton A. 2010. Instruments, randomization, and learning about develop-
ment. Journal of Economic Literature 48: 424–55.
Duflo E, Dupas P, Kremer M. 2011. Peer effects, teacher incentives, and the
impact of tracking: evidence from a randomized evaluation in Kenya.
American Economic Review 101: 1739–74.
Duflo E, Kremer M, Glennerster R, 2008. Using randomization in develop-
ment economics research: a toolkit. In: Schulz T, Strauss J (eds). Handbook
of Development Economics. Amsterdam: North Holland.
Finkelstein A, Taubman S, Wright B et al. 2012. The Oregon health insurance
experiment: evidence from the first year. Quarterly Journal of Economics
127: 1057–106.
Heckman JJ. 2010. Building bridges between structural and program evalu-
ation approaches to evaluating policy. Journal of Economic Literature 48:
356–98.
Heckman JJ, Smith JA. 1995. Assessing the case for social experiments.
Journal of Economic Perspectives 9: 85–110.
Ioannidis J, Stanley T, Doucouliagos H, 2017. The power of bias in economics
research. Economic Journal 127: F236–65.
Kling JR, Liebman JB, Katz LF. 2007. Experimental analysis of neighborhood
effects. Econometrica 75: 83–119.
Ludwig J, Kling JR, Mullainathan S. 2011. Mechanism experiments and policy
evaluations. Journal of Economic Perspectives 25: 17–38.
Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A. 1987. Health
insurance and the demand for medical care: evidence from a randomized ex-
periment. American Economic Review 77: 251–77.
Medley GF, Hollingsworth TD, Olliaro PL, Adams ER. 2015. Health-seeking
behaviour, diagnostics and transmission dynamics in the control of visceral
leishmaniasis in the Indian subcontinent. Nature 528: S102–8.
Miguel E, Kremer M. 2004. Worms: identifying impacts on education and
health in the presence of treatment externalities. Econometrica 72: 159–217.
Moore GF, Audrey S, Barker M et al. 2015. Process evaluation of complex
interventions: Medical Research Council guidance. BMJ 350: h1258.
Pettifor A, MacPhail C, Selin A et al. 2016. HPTN 068: a randomized control
trial of a conditional cash transfer to reduce HIV infection in young women
in South Africa—study design and baseline results. AIDS Behavior 20:
1863–82.
Smith P, Morrow R, Ross D. 2015. Field Trials of Health Interventions: A
Toolbox. New York: Oxford University Press.
Todd PE, Wolpin KI. 2006. Assessing the impact of a school subsidy program
in Mexico: using a social experiment to validate a dynamic behavioral
model of child schooling and fertility. American Economic Review 96:
1384–417.
Turner RM, Bird SM, Higgins JP. 2013. The impact of study size on
meta-analyses: examination of underpowered studies in Cochrane reviews.
PLoS One 8: e59202.
Warren E. 2016. Strengthening research through data sharing. The New
England Journal of Medicine 375: 401–3.
White RG, Glynn JR, Orroth KK et al. 2008. Male circumcision for HIV
prevention in sub-Saharan Africa: who, what and when?AIDS 22: 1841–50.
Health Policy and Planning, 2018, Vol. 0, No. 0 5
Downloaded from https://academic.oup.com/heapol/advance-article-abstract/doi/10.1093/heapol/czy028/4955260
by London School of Hygiene & Tropical Medicine user
on 02 May 2018
